Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Psychedelic Pharmaceutical Startup Ninnion Announces Patent Filings and Development of NIN-S119 for Ischemic Stroke

Ninnion

Ninnion, a clinical-stage pharmaceutical company focused on developing next-generation psychedelic therapeutics, today announced the commencement of a first-of-its-kind pre-clinical development of NIN-S119. NIN-S119 is a proprietary, short-acting substituted tryptamine to treat patients recovering from ischemic stroke. It would be the first drug of its kind in the treatment of stroke, potentially making it eligible for Breakthrough Therapy designation by the FDA, a designation that can accelerate the development timeline. “Ninnion saw a big opportunity to develop NIN-S119, as there are no approved drug therapies for patients recovering from a stroke. It will be used in conjunction with physical/occupational therapy to enhance stroke recovery by inducing neuroplasticity – meaning it induces the formation of new connections between nerve cells in the brain. This sort of brain ‘rewiring’ could prove beneficial for stroke recovery by creating new brain circuitry that could restore function to brain areas damaged by stroke,” said Bill W Massey, Chief Development Officer of Ninnion. While drugs of this class that produce neuroplastic effects can induce psychedelic experiences (e.g. LSD, mescaline, DMT, etc.), one major benefit of NIN-S119 is that even though it's in this class of drugs, it could potentially be administered in low doses that do not produce these experiences. This would make NIN-S119 much easier to use clinically, reducing the time and effort of clinical staff and opening the potential for administration by the patient at home. “After experiencing multiple health issues, including three strokes in one year, I began researching and reading all about how to repair the brain through the neuroplasticity and neurogenesis effects of psychedelics. We created Ninnion to not only develop a new way to treat strokes but more importantly, to bring these drugs to market in a responsible way. The way psychedelic therapies are set up now is not helpful for the payer-reimbursed market. We want to create therapies that are accessible and affordable; patients should not have to pay thousands of dollars for therapies out of pocket. We’re encouraged by recent patent approvals for the development and delivery of new psychedelic therapies and we’re looking forward to advancing our clinical trials and continuing to develop other molecules in our pipeline,” said Jeremy M Caudill, Founder, and CEO of Ninnion. Ninnion’s research and development efforts currently focus on advancing next-generation psychedelic therapies, which will ultimately empower patients with more accessible and affordable treatment opportunities. To find out more about the study and Ninnion’s NIN-S119 molecule, visit www.ninnion.com/. About Ninnion Headquartered in Austin, Texas, Ninnion is a pharmaceutical company on a mission to build a fully integrated pharmaceutical psychedelics eco-system leveraging the latest AI drug discovery, development, cGMP manufacturing, commercialization, patient clinics and specialty pharmacy distribution network designed for the next frontier of psychedelic medicine. Focused on the payer-reimbursed market, Ninnion has begun developing a pipeline of next generation psychedelic therapies with a clinical focus on brain injury, chronic pain, inflammation, and addiction disorders. To learn more, visit www.ninnion.com. Contact Details Jive PR + Digital Ashley Areeda +1 734-891-4013 aareeda@jiveprdigital.com

April 07, 2022 11:33 AM Eastern Daylight Time

COD Mammography Program Acquires Cutting-Edge, Hospital-Grade Equipment

College of DuPage

Mammography program students at College of DuPage now have access to more specialized training, thanks for the addition of new field-specific equipment. The innovative digital technology, Hologic Tomosynthesis 2D and 3D mammography machines, typically are available at hospitals and clinical settings and rarely on a college campus, said COD Diagnostic Medical Imaging Assistant Professor and Mammography Program Chair Sue Dumford. “The new equipment gives students an added advantage to be able to practice their skills in the classroom before having to use it on real patients during clinical rotations at hospitals and clinics,” she said. “Students will be able to practice on other classmates as well as on model torsos with soft breasts. Having the machines in front of students also allows us to teach about quality assurance and quality control.” The Mammography program at COD is a one-semester post-radiography advanced certificate program available to graduates of an accredited Radiography program. Many of the students enrolled in the Mammography program are graduates of COD’s two-year Radiography program. "I’m proud to say that we maintain a 100 percent American Registry of Radiologic Technologists registry pass rate and that our graduates are recognized as excellent entry-level mammographers,” Dumford said. Tara Logan decided to pursue a career in mammography after working at the front desk of a general surgery office. “One of the doctors in my office was a breast surgeon,” she said. “Every day he worked with breast cancer patients, and I will never forget how he made them feel. When people are going through some of the toughest days of their life, they need someone to lean on, and I wanted to be that person for them.” Logan graduated from COD’s Radiography program in 2020 earning an Associate in Applied Science in Diagnostic Medical Imaging before earning an advanced certificate in Mammography in 2021. “The program truly prepared me for a long career in breast imaging, and I’m so lucky to have been a part of both COD’s Radiography and Mammography programs,” she said. “With the two mammography units, I was able to learn correct positioning skills and then go out into the field and practice on real patients. Cancer screening is something that will always be needed, and your patients will always need you. Apply to the program and start making a difference in the way females feel about health care.” Learn more about the COD Mammography program. Learn more about COD’s Radiography program. Contact Details College of DuPage Angela Mennecke +1 630-942-3134 menneckea@cod.edu

April 07, 2022 08:00 AM Central Daylight Time

Image

Cloudrise Is Taking 2022 By Storm

Cloudrise

Cloudrise Inc., a technology-enabled services firm focused on data protection, cloud security, and privacy, continues to make waves with a flurry of exciting news to kick-off 2022. Cloudrise is pleased to announce the acquisition of CyberOrchard, an information security managed service organization located in the United Kingdom. Cloudrise CEO, Rob Eggebrecht, shared his thoughts: “The merger of the two companies brings a breadth of knowledge and expertise to Cloudrise, paving the way to expand our portfolio of data protection services to the global market.” As part of the acquisition, Jason Bird, CyberOrchard’s Founder and CEO, has been named Chief Technology Officer (CTO) at Cloudrise. Bird has over 25 years of experience in cybersecurity, managed services, data governance, and privacy. “Data protection is becoming more complex every day, and at Cloudrise we believe collaboration is the path to better protection for our customers. We are partnering with the strongest data-centric technology companies to bring innovative solutions to our customers, such as Netskope, AWS, Digital Guardian, Microsoft, OneTrust, Varonis, BigID, and Veritas, just to name a few,” said Bird. This news comes just a week after Netskope named Cloudrise as their Global Services Partner of the Year. “This achievement illustrates Cloudrise’s commitment to delivering innovative service offerings to customers worldwide,” said Joe Infantino, Chief Operating Officer at Cloudrise. Additionally, Cloudrise is pleased to announce that CRN®, a brand of The Channel Company, has named Cloudrise to its Managed Service Provider (MSP) 500 list in the Managed Security 100 category for 2022. Winners are recognized for helping end users increase efficiency, simplify solutions, and maximize their return on investment. Cloudrise is taking 2022 by storm and encourages its followers to stay tuned for future announcements. About Cloudrise Cloudrise is a technology-enabled services firm, specializing in delivering data-centric services customized to meet organizations’ business needs. Drawing from 20+ years of experience in the field, they have tailored their services to be focused on securing organizations’ data wherever it resides. Cloudrise knows how to identify gaps, build and optimize controls and integrations across the enterprise, and deploy data-centric technologies across multiple industries, geographies and organizational sizes – all with the expertise to navigate an ever-changing data compliance and regulatory landscape. Cloudrise can be found at Cloudrise.com or on LinkedIn. About CyberOrchard UK-based CyberOrchard is an information security managed services organization, home to experts with over 20 years of data security experience. Whether the risk to organizations' data lives in transit on the network, at rest in storage, or in use at an endpoint, CyberOrchard provides the necessary data security bundled service offerings, consultancy and managed services to significantly reduce organizations' risk of data loss. CyberOrchard can be found at cyberorchard.com or on LinkedIn. Contact Details Jodi Lewis +1 800-917-7619 sales@cloudrise.com Company Website https://cloudrise.com/

April 06, 2022 07:00 AM Mountain Daylight Time

Lancer Dermatology Announces Partnership with Forefront Dermatology

Lancer

Premier Beverly Hills-based dermatology practice, Lancer Dermatology, announced today that it has partnered with Forefront Dermatology, the largest physician-led single specialty group providing dermatological services in the United States with over 200+ dermatology practices. The collaboration with Forefront Dermatology will serve to expand the world-renowned legacy of the Lancer Dermatology practice through satellite clinics in select additional markets across the United States. Since opening the clinic in 1983, Dr. Harold Lancer has grown his Beverly Hills-based dermatology practice into a world-renowned mecca with a celebrity cult-following. Currently, the practice is a global destination for celebrities, socialites, and even members of royal families. Dr. Lancer’s work ethic, integrity, approach, and results make him one of the most sought-out dermatology professionals, piquing the interest of Forefront Dermatology. The team at Lancer Dermatology consists of tenured nurses and skilled aestheticians who have been personally trained by Dr. Lancer to deliver the highest level of service and care to their patients. The partnership between Lancer Dermatology and Forefront Dermatology will allow the legacy and state-of-the-art care that Lancer Dermatology is known for worldwide, to expand beyond the Beverly Hills clinic for many years to come. By opening satellite locations across the nation, even more patients will be able to experience the state-of-the-art care that Lancer Dermatology is celebrated for, even if they are unable to visit the Beverly Hills practice. “The highlight of my career was when I opened the doors to my Beverly Hills clinic in 1983, and every day since then I have had the pleasure of treating my patients with unparalleled care. I am proud to partner with Forefront Dermatology to extend the legacy we have created at Lancer Dermatology to make our state-of-the-art experience and treatments even more accessible,” said Dr. Harold Lancer, Board-Certified Dermatologist and Founder of Lancer Dermatology and Lancer Skincare. “For many years, we have had the goal to extend the state-of-the-art approach of Lancer Dermatology practice beyond the Beverly Hills clinic. When Forefront Dermatology approached our team, it was clear that their preeminent expertise in expansion was in perfect alignment with our goals. Through this partnership, we are thrilled to be expanding our legacy, without sacrificing on quality of care,” said Tracey Sameyah, CEO of Lancer Skincare. “Our partnership with Dr. Lancer and the Lancer Dermatology Team is consistent with our approach to partnering with Board-Certified Dermatologists and Surgeons that are committed to physician leadership, innovation, and exceptional patient experiences and outcomes. We are thrilled to partner with Dr. Lancer on expanding access to dermatology care and leveraging the expertise and strong reputation he has garnered over the past 30 years,” said Betsy J. Wernli, MD, President of Forefront Dermatology. The Beverly Hills clinic will remain unaffected by the partnership, with no changes being made to the day-to-day operations or existing staff of distinguished nurses and aestheticians. Dr. Lancer’s international skincare brand, Lancer Skincare, will also remain a separate entity, owned solely by Dr. Lancer, with no changes to the award-winning products that bring to life his philosophy of “from practice to product.” Lancer Dermatology is moving faster than ever to make its state-of-the-art care and approach more accessible and available to everyone. For more information about Lancer Dermatology, please visit LancerSkincare.com or @drlancerrx. About Lancer Dermatology The goal at Lancer Dermatology is to provide each patient with expert skin care and a personalized, first-class experience. Lancer Dermatology offers state-of-the-art care in aesthetic, cosmetic, medical and surgical dermatology treatments. The Lancer Dermatology team consists of tenured nurses who have been personally trained by Dr. Lancer to deliver the highest level of service and care to our patients. Dr. Lancer believes that the best way to foster trust and commitment amongst patients is to have a knowledgeable and familiar team at his side. The Lancer Nursing Team is an elite and talented group of professionals who are always on hand to assist with all patient consultations and procedures. Dr. Lancer's skilled aestheticians possess decades of experience providing customized services and treatments to patients. Trained by Dr. Lancer himself, the aesthetician team is comprised of multilingual, highly-professional and sought-after experts who are proficient in The Lancer Method protocols as well as all of the Services & Technologies offered exclusively at the Lancer Dermatology Clinic. With revolutionized procedures and tools, the team is able to provide a personalized, best-in-class experience to every patient. About Forefront Dermatology Located throughout the East, Midwest, Mid-Atlantic, Southwest, Southeast and West, Forefront Dermatology is a large and growing, physician-led, single-specialty group practice comprising 200+ dermatology practices. Forefront's community-based, Board-Certified Dermatologists and specialists provide best-in-class general, surgical and cosmetic dermatological care along with related laboratory services. Headquartered in Manitowoc, WI, Forefront's Board-Certified Dermatologists and medical specialists are dedicated to providing the highest standard of care for conditions of the hair, skin, and nails to people of all ages and stages of life. Using innovative and proven solutions, Forefront's caring, Board-Certified Dermatologists and medical specialists treat the total patient to help improve not only the condition of their skin, but also their quality of life. To learn more, visit www.ForefrontDermatology.com. Contact Details OGAKI Malinda Torres +1 646-475-7056 mtorres@ogakidigital.com Company Website https://www.lancerskincare.com/

April 04, 2022 09:00 AM Eastern Daylight Time

Green Cubes Technology Announces Membership in CircuBAT Research Program

Green Cubes Technology

Green Cubes Technology, a leader in electrification and Lithium power solutions, today announced its participation as a founding member in CircuBAT. CircuBAT is a Swiss research program that aims to create a Swiss circular business model for the production, application, and recycling of Lithium-ion batteries. Seven Swiss research institutions and 24 companies are joining forces to look for ways to boost sustainability in all stages of a battery’s life cycle. CircuBAT will focus on finding solutions that boost sustainability in all phases of a Lithium-ion battery’s life cycle. This will include extending the lifespan of batteries during their first application. Researchers hope to achieve this by developing optimal charging and discharging strategies as well as new concepts for battery construction that make repairs easy. The project also aims to put batteries to use as stationary energy storage systems after they are retired from their first mobility-related application. To that end, CircuBAT will look at the best ways of integrating these batteries at a local level and ensuring their safe and efficient operation. Finally, the researchers will look for solutions for remanufacturing batteries and recovering materials that enable large quantities of high-quality secondary raw materials to be used to produce new batteries. Bern University of Applied Sciences BFH is the Leading House in the CircuBAT project. On the science side, an additional six Swiss research institutions are involved in the project: Empa, the Swiss Center for Electronics and Microtechnology (CSEM), the University of St. Gallen (HSG), the Eastern Switzerland University of Applied Sciences (OST), the Switzerland Innovation Park Biel / Bienne (SIPBB) and the EPFL (Swiss Federal Institute of Technology). These institutions are joined by 24 companies from economy and industry, among them Kyburz, Leclanché, Bühler and Green Cubes Technology. As a founding member of CircuBAT, Green Cubes Technology has made a multi-year financial investment in the program. The company will also contribute first-use lithium-ion batteries for experimentation and testing within the program, provide engineering design services to develop new more-efficient batteries, and contribute intellectual property to achieve the objectives of CircuBAT. Green Cubes Technology will participate in two working groups. The “First Use” group will focus on extending the life of first-use batteries through extensive analysis of deployed batteries in the field. Green Cubes Technology will contribute performance data collected from its prolific installed base of Lithium-ion batteries. The “Second Life” group will focus on creating second-use and second-life opportunities to minimize the total CO 2 footprint of lithium-ion battery systems during their lifetime. Since its inception 30 years ago, Green Cubes Technology has gained considerable experience minimizing the environmental impact of its deployed batteries. This positive impact will be amplified with a system of second life batteries, where the installed base of first use batteries is redeployed when they reach a certain age limit. The Lithium-ion cells used in Green Cubes Technology’s batteries are non-toxic, and are currently recycled and reprocessed at their end of life. Going forward, these cells can be repurposed into less demanding second life applications such as backup energy storage. “We joined the CircuBAT research program because its mission is very well aligned with ours,” said Keith Washington, CEO of Green Cubes Technology. “We all want the same thing and that is a circular economy for Lithium-ion batteries. We are looking forward to sharing our experience, and giving electric mobility batteries a second life with our Swiss partners in the CircuBAT research program, as they strive to make the Swiss economy as sustainable as possible” More information on the research program can be found on its website: https://circubat.ch. About Green Cubes Technology Green Cubes Technology develops and manufactures safe and reliable electrification solutions that enable its OEM and enterprise customers to transition from Lead Acid and Internal Combustion Engine (ICE) power to Lithium-ion battery power. Green Cubes utilizes proven hardware and software platforms to build the most reliable Lithium power solutions in its industries. With over 300 employees across six countries, Green Cubes has been producing innovative, high-performance and high-quality power solutions since 1986. More information can be found at https://greencubestech.com. Contact Details Ray Young (General Media, Investor Relations) +1 916-505-4245 ray@razorsharppr.com Hayley Luz (Trade Media) +1 425-918-2742 hluz@greencubestech.com Company Website https://greencubestech.com/

March 31, 2022 10:00 AM Eastern Daylight Time

CORRECTING and REPLACING G Medical Innovations takes aggressive approach to protect shareholders by combatting naked shorting of GMVD shares with an investigation to end the criminal activity

G Medical Innovations Holdings

This release issued on March 30, 2022 is being replaced with the following corrected version due to multiple revisions. The updated release reads: G Medical Innovations (NASDAQ: GMVD) takes aggressive approach to protect shareholders by combatting naked shorting of GMVD shares with an investigation to end the criminal activity Poised for expansion and growth, the company continues to process thousands of COVID-19 PCR and rapid antigen/flu testing; and its personal healthcare monitoring business expects sales growth G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) takes aggressive approach to protect shareholders by combatting naked shorting of GMVD shares with an investigation to end the criminal activity and ensure perpetrators will face aggressive legal action in the interest of protecting shareholders. G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) announced that it has investigated aggressive naked short sales of its stock and is confident that it has identified the perpetrators of this illegal activity. The company will defend its shareholders by taking all regulatory and legal action against this criminal activity. It has instructed its legal department to contact the SEC, FINRA, and NASDAQ to conduct full investigations on their ends. G Medical continues to demonstrate growth and commitment to expansion across its business units. Its wholly owned subsidiary, G Medical Tests and Services, Inc. as well as G-Medical Lab Services Inc., continues to process thousands of COVID-19 PCR and rapid antigen/flu tests from its sites and its personal healthcare monitoring business expects sales growth via negotiations with major health systems and is prepared for increased testing capacity, given new virus variants expected to emerge. In addition, G Medical Innovations is involved in negotiations with numerous hospitals and healthcare systems for sales of its Prizma Care remote patient monitoring devices and services. Patients, cardiologists, and health providers across the country rely on G Medical’s innovative Prizma monitoring devices and services for accurate and reliable remote monitoring. The company is planning a shareholder’s conference call soon. At that time, it will report on achievements during Q1 2022. About G Medical Innovations G Medical Innovations Holdings Ltd. is an early commercial-stage healthcare company engaged in the development of next-generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease, and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical-grade device that can transform almost any smartphone into a medical monitoring device, enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous, and real-time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. Visit https://gmedinnovations.com/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, G Medical is using forward-looking statements when it discusses that it continues to process thousands of COVID-19 PCR and rapid antigen/flu tests from its sites and is prepared for increased testing capacity, given new virus variants expected to emerge. Because such statements deal with future events and are based on G Medical’s and McDade Products’ current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of G Medical and McDade Products could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in G Medical’s prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission (“SEC”) on June 28, 2021, the registration statement on Form F-1 filed on February 14, 2022 (registration no. 333-262724) and in any subsequent filings with the SEC. Except as otherwise required by law, the companies undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. G Medical and McDade Products are not responsible for the contents of third-party websites. Contact Details Kobi Ben-Efraim, CFO +972 8-958-4777 service@gmedinnovations.com Company Website https://gmedinnovations.com/

March 30, 2022 12:26 PM Eastern Daylight Time

Modivcare Awarded ISO 27001 Security Certification

Modivcare

Modivcare Inc. (“Modivcare”) (Nasdaq: MODV), a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions focused on improving patient outcomes, today announced it has been awarded ISO 27001 certification for its non-emergency medical transportation division. ISO 27001 is an international information security management standard published by the International Organization for Standardization (ISO) – the world's largest developer of voluntary international standards – and the International Electrotechnical Commission (IEC). Unlike other certifications and compliance attestations that are much narrower in scope, ISO 27001 is a broad-spectrum certification that speaks to the health and robustness of an organization’s overall information security program. ISO 27001 sets out requirements for Modivcare’s information security management system to ensure the protection of sensitive data. The certification confirms that Modivcare operates a fundamentally sound, risk-focused professional security program based on an open security standard that has been tested for decades. Adhering to this standard enables Modivcare to manage the security of assets such as financial information, intellectual property, employee details, or information entrusted by third parties. “A company’s information security program sets the foundation for its ability to provide secure solutions, such as defending against and recovery from cyberattacks or preventing the loss of sensitive data,” said Modivcare Chief Information Officer, Walt Meffert. “This certification is significant because it tells our patients and customers that they can be confident their data is secure within our environment.” Modivcare’s non-emergency medical transportation (NEMT) services provide patients access to safe and reliable rides to health services. Working with local, community-based transportation providers, Modivcare is the largest broker of NEMT in the nation and brings more than 35 years of experience to its transportation providers and more than 75 million trips managed annually for 30 million patients across the United States. About Modivcare Modivcare Inc. (“Modivcare”) (Nasdaq: MODV) is a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions for public and private payors and their patients. Our value-based solutions address the social determinants of health (SDoH), enable greater access to care, reduce costs, and improve outcomes. We are a leading provider of non-emergency medical transportation (NEMT), personal and home care, remote patient monitoring, medication management and meal delivery. Modivcare also holds a minority equity interest in CCHN Group Holdings, Inc. and its subsidiaries (“Matrix Medical Network”), which partners with leading health plans and providers nationally, delivering a broad array of assessment and care management services to individuals that improve health outcomes and health plan financial performance. To learn more about Modivcare, please visit www.modivcare.com. Contact Details Media Kate Zerone, Director, Ombudsman & Communications kate.zerone@modivcare.com Amendola Communications Kim Warth kwarth@acmarketingpr.com

March 30, 2022 09:30 AM Eastern Daylight Time

Industrial Defender and GrayMatter Team Up to Equip Energy and Water Companies with Holistic Cybersecurity Defenses

Industrial Defender

Industrial Defender, the leader in operational technology (OT) security and GrayMatter, the top digital transformation services firm for industrial companies, announced today that they are teaming up to offer comprehensive cybersecurity solutions for critical infrastructure. Industrial organizations seek out GrayMatter to assess their OT cybersecurity needs and curate the best technologies available, and the Industrial Defender platform is now an essential part of their technology offerings. GrayMatter's deep experience in the manufacturing, utility and water/wastewater industries complements Industrial Defender's focus on providing the foundational cybersecurity controls that protect critical infrastructure. Industrial Defender and GrayMatter follow a five-part approach to strengthening cybersecurity based on the NIST Cybersecurity Framework (CSF), and they both understand that operational technology environments demand unique cybersecurity solutions. “Partnering with GrayMatter is a huge win for critical infrastructure companies,” said Jim Crowley, CEO of Industrial Defender, “GrayMatter’s deep market knowledge and digital transformation expertise, combined with our cutting-edge OT data collection and normalization software provides them with the people, process and technology to build the strongest cybersecurity defenses possible.” "We're excited to partner with Industrial Defender," says GrayMatter Co-Founder and CEO James Gillespie, "Like us, they've been helping companies strengthen their OT cybersecurity for years, and they specialize in energy, water/wastewater and other critical industries that have made it a priority to stay ahead of new vulnerabilities and regulations." The Industrial Defender platform empowers organizations to turn cybersecurity data into action by safely collecting, monitoring, and managing OT endpoint and network data at scale. With just a few clicks, Industrial Defender also provides the necessary data to measure a security program against many different standards, including the NIST CSF. To learn more about this partnership, contact Industrial Defender at www.industrialdefender.com or GrayMatter at www.graymattersystems.com. About Industrial Defender Since 2006, Industrial Defender has been solving the challenge of safely collecting, monitoring, and managing OT asset data at scale, while providing cross-functional teams with a unified view of security. Their specialized solution is tailored to complex industrial control system environments by engineers with decades of hands-on OT experience. Easy integrations into the broader security and enterprise ecosystem empower IT teams with the same visibility, access, and situational awareness that they’re accustomed to on corporate networks. Learn more at www.industrialdefender.com. About GrayMatter GrayMatter’s goal is to transform operations and empower people. Since 1991, we have been helping some of the biggest industrial organizations in the world harness data so they can work smarter. They lean on us to secure their critical systems and connect their industrial assets to their teams so that every operator is empowered to be the best operator. GrayMatter has been on the Inc. 5000 fastest-growing companies list for six consecutive years and has grown to provide Advanced Industrial Analytics, OT Cybersecurity, Digital Transformation and Automation & Control services to clients in CPG, energy, food & beverage, manufacturing and water/wastewater industries across the U.S. and Canada. Learn more at graymattersystems.com. Contact Details Industrial Defender Erin Anderson +1 617-675-4206 eanderson@industrialdefender.com Company Website https://www.industrialdefender.com

March 29, 2022 09:00 AM Eastern Daylight Time

UNOS Receives Over $800,000 in Grant to Support Organ Tracking Tech

United Network for Organ Sharing

S.L. Gimbel Foundation, a component fund at the Inland Empire Community Foundation, recently awarded United Network for Organ Sharing (UNOS) an $836,208 grant to support two innovative tools: the UNOS Organ Tracking Service and the UNOS Travel App. UNOS is the engine that powers the national organ donation and transplantation system. “UNOS continues to harness the power of modern technology and meaningful collaborations to ensure that lifesaving donor organs continue to get where they need to go,” UNOS CEO Brian Shepard said. “Both the tracking service and the travel app are the most recent examples of how we’re working to provide donor families, recipient families, patients and medical professionals with the peace of mind they need, and I am proud that our team continues to develop evidence-based, tech-driven solutions that save even more lives.” "The S.L. Gimbel Foundation Fund is proud to support the important work of UNOS and the innovative tools they're using to help organ donors and recipients across the country," said Celia Cudiamat, SVP of Grants and Community Impact at IECF. "It is a great privilege to disperse these funds on their behalf, knowing their desire to focus on human dignity issues as a priority in their giving." UNOS Organ Tracking Service Developed by UNOS and tested by organ procurement organizations (OPOs) across the country, the service is now in use by 13 of the nation’s 57 OPOs. With this service, OPOs and transplant hospitals know when an organ is in transit, when it arrives at an airport, when the flight departs, and when the organ has arrived at its destination, all in real time. The grant will fund the continued expansion of the tracking service, providing upgraded technology, a suite of advanced notifications including travel predictions, and other improvements. This will provide OPOs with an even more reliable, user-friendly way to track organs in transit. UNOS Travel App Select OPOs began piloting the UNOS Travel App in late 2020. The tool helps OPOs make more informed transportation plans by providing them with a view of all available options, including flight schedules, driving directions, travel times and other useful information. The grant will pave the way for the full deployment of the UNOS Travel App, making it possible to integrate this service into the current organ offer system, assisting both OPOs and transplant hospitals with logistical decisions. This generous grant comes after a year of historic firsts for UNOS and the entire donation and transplant community, including surpassing 41,000 transplants in a single year for the first time in 2021, as well as record-breaking numbers of kidney, heart, and liver transplants. ### About United Network for Organ Sharing United Network for Organ Sharing (UNOS) is the mission-driven non-profit serving as the nation’s transplant system under contract with the federal government. We lead the network of transplant hospitals, organ procurement organizations, and thousands of volunteers who are dedicated to honoring the gifts of life entrusted to us and to making lifesaving transplants possible for patients in need. Working together, we leverage data and advances in science and technology to continuously strengthen the system, increase the number of organs recovered and the number of transplants performed, and ensure patients across the nation have equitable access to transplant.. About the Inland Empire Community Foundation Founded in 1941, the Inland Empire Community Foundation is the oldest and largest community foundation in Inland Southern California. We partner with individuals, families and corporations to help them achieve their charitable goals. Since inception, we have given out over $124 million in grants and scholarships. For more information visit the IECF’s website at www.iegives.org. Be a part of our conversation on Facebook, Twitter and LinkedIn. Contact Details Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

March 25, 2022 04:06 PM Eastern Daylight Time

1 ... 189 190 191 192 193 ... 249